🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This is a very nice summary of all major trials of revascularization in stable CAD w/ Andrew Foy & John Mandrola, MD

OAT is a very important trial in cardiology. It showed that PCI didn’t improve outcomes in pts with late presenting STEMI. As Andrew Foy pointed out, if opening an included artery didn’t help here, under what circumstances could be possibly helpful? Andrew Foy & John Mandrola, MD

Previous obs studies suggest that left atrial appendage occlusion reduce mortality Mohammed Ruzieh, MD et al do a more careful analysis of the same Medicare database and confirm the findings of RCTs that pLAAO does not reduce mortality at one year. Impressive work

Happy to share our latest work regarding assessment of the right ventricle in intermediate risk PE patients in JAHA ⁦Michael Pfeiffer⁩ ⁦Brandon Peterson⁩ ⁦Mohammed Ruzieh, MD⁩ search.app/h6eF3irW7wgc5p…

John Gorcsan III, MD Michael Pfeiffer Brandon Peterson Mohammed Ruzieh, MD

Not everyone with NSTEMI should go to the cath lab, and you should be more and more selective in older patients Listen to our discussion Cardiology Trials with Andrew Foy and John Mandrola, MD

We have reviewed 84 seminal trials Cardiology Trials w/ Andrew Foy & John Mandrola, MD These trials covered the topics of stable CAD and acute coronary syndromes. We will be reviewing heart failure trials next and you will see many surprises then! Follow our substack cardiologytrials.substack.com

A really eye-opening review of the Dig Trial over at Cardiology Trials I don't know you all...digoxin should not be demonized. Take a read or listen to Andrew Foy review cardiologytrials.substack.com/p/review-of-th…

Guidelines still recommend using beta-blockers after MI. Mohammed Ruzieh, MD and Andrew Foy explain that the evidence underpinning this practice is outdated. And newer trials fail to confirm beta-blocker benefit. This is a classic case of evidence requiring an expiration date.

I just recorded an excellent podcast with Andrew Foy Mohammed Ruzieh, MD on the below HF trials. Coming Friday on Cardiology Trials I learn so much from these two. Teaser: there is a bunch of nuance in our GDMT evidence